BRKR vs. BIO, AVTR, WAT, TXG, PACB, QTRX, AXDX, MTD, A, and AZPN
Should you be buying Bruker stock or one of its competitors? The main competitors of Bruker include Bio-Rad Laboratories (BIO), Avantor (AVTR), Waters (WAT), 10x Genomics (TXG), Pacific Biosciences of California (PACB), Quanterix (QTRX), Accelerate Diagnostics (AXDX), Mettler-Toledo International (MTD), Agilent Technologies (A), and Aspen Technology (AZPN).
Bruker (NASDAQ:BRKR) and Bio-Rad Laboratories (NYSE:BIO) are both computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
In the previous week, Bruker had 3 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 5 mentions for Bruker and 2 mentions for Bio-Rad Laboratories. Bruker's average media sentiment score of 1.07 beat Bio-Rad Laboratories' score of 0.16 indicating that Bruker is being referred to more favorably in the media.
Bruker presently has a consensus price target of $84.29, indicating a potential downside of 10.20%. Bio-Rad Laboratories has a consensus price target of $493.75, indicating a potential upside of 41.25%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bruker.
Bruker has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.
Bruker has a net margin of 14.41% compared to Bio-Rad Laboratories' net margin of -23.86%. Bruker's return on equity of 29.94% beat Bio-Rad Laboratories' return on equity.
79.5% of Bruker shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 28.2% of Bruker shares are held by company insiders. Comparatively, 17.1% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Bruker received 306 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. However, 65.10% of users gave Bio-Rad Laboratories an outperform vote while only 64.98% of users gave Bruker an outperform vote.
Bruker has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.
Summary
Bruker beats Bio-Rad Laboratories on 14 of the 17 factors compared between the two stocks.
Get Bruker News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRKR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools